Biologic Infusion Therapy

Biologics are medicines made from proteins produced in living cells, most often antibodies designed to recognise one target in the immune system. In inflammatory diseases the immune system attacks the body's own joints, spine, skin or bowel, driven by chemical messengers such as tumour necrosis factor, interleukin 6 or interleukin 17, and by particular types of white blood cell. Each biologic blocks one of these pathways. Medicines given by infusion include infliximab, which blocks tumour necrosis factor; tocilizumab, which blocks interleukin 6; rituximab, which removes a group of immune cells called B cells; abatacept, which dampens T cell activation; and vedolizumab, which stops inflammatory cells entering the bowel wall. Some other biologics are given as injections under the skin at home. Biosimilars are versions of an original biologic made once its patent has expired. They are tested to show no meaningful difference in effect or safety and are now used routinely in many health systems.

Biologics are recommended when an inflammatory disease remains active despite standard treatment, or when the disease is severe enough to need targeted control early. In rheumatoid arthritis, they are usually added when conventional disease-modifying medicines such as methotrexate have not controlled joint swelling and pain. In ankylosing spondylitis and other forms of axial spondyloarthritis, they are used when anti-inflammatory painkillers and exercise are not enough. In psoriatic arthritis, they help both the joints and often the skin. In Crohn's disease and ulcerative colitis of moderate to severe activity, they are used to bring the bowel under control and keep it there, and can help heal fistulas in Crohn's disease. Biologics are also used in some forms of vasculitis, lupus, uveitis and other immune conditions. The choice of medicine depends on the diagnosis, previous treatments, other health problems, plans for pregnancy and practical factors such as how often you can attend for infusions.

The medicine is given through a small cannula in a vein in the arm, connected to a drip that runs slowly over a set time, in a comfortable chair in an infusion centre. Before each infusion a nurse checks your temperature, pulse and blood pressure, asks about infections and reviews recent blood tests. Some medicines are preceded by tablets or an injection that reduce the chance of a reaction. An infliximab or vedolizumab infusion usually takes about 30 minutes to 2 hours, tocilizumab about an hour, and a rituximab infusion several hours, especially the first time. You are observed for a short period afterwards. Treatment begins with starting doses that are closer together, for example at weeks 0, 2 and 6 for infliximab or vedolizumab, followed by regular maintenance infusions, typically every 4 to 8 weeks. Rituximab is given as two infusions about two weeks apart, repeated about every 6 months. Blood tests are checked at intervals throughout.

Before starting, the diagnosis and the level of disease activity are confirmed with examination, blood tests and imaging or endoscopy. Screening is essential because biologics weaken some defences against infection. You are tested for latent tuberculosis, usually with a blood test and a chest X-ray, and for hepatitis B and C, and often for HIV; if latent tuberculosis is found, preventive treatment is started before the biologic. Vaccinations are reviewed, and live vaccines are given before treatment starts rather than during it. The team asks about heart failure, previous cancer, nerve conditions and current infections, which may favour one medicine over another, and about pregnancy plans. For international patients, previous results, scans and treatment history can usually be reviewed remotely, so the screening tests and the first infusion can be organised soon after arrival. It also helps to confirm in advance that the chosen medicine, or its biosimilar, is available near home to continue treatment.

There is no recovery period in the surgical sense. Most people feel well after an infusion and return to work or normal activities the same or the next day, although some notice tiredness or a mild headache. Because treatment continues for months or years, the key planning question is how much to do abroad. A practical approach is to complete the diagnosis, screening and starting doses abroad, then continue maintenance infusions near home under a written plan shared with your home specialist, covering the exact medicine, product, dose, interval and blood monitoring. Some people with long intervals between doses, such as rituximab twice a year, choose to return for each course. If you travel during treatment, plan trips around infusion dates, carry a letter describing your medicines, and seek prompt advice for fever or signs of infection. Keeping to the same product where possible avoids unplanned switches between different versions.

Biologics have been used for more than two decades, and their benefits and risks are well understood. The most common problems are infusion reactions, such as flushing, itching, headache or a change in blood pressure, which are usually mild and managed by slowing the drip or giving medicine; severe allergic reactions are rare and the unit is equipped to treat them. Because the immune system is dampened, infections are more likely, including chest and urinary infections, shingles and, rarely, reactivation of tuberculosis or hepatitis B, which is why screening matters. Some medicines can affect blood counts, liver tests or cholesterol, so blood checks continue throughout. Less common concerns depend on the medicine and include effects on heart failure, nerves or certain skin cancers. Many people notice improvement within weeks, and the full effect is usually judged after 3 to 6 months. If one biologic does not work well, or stops working, another with a different target can often be tried.